| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 08/23/2001 | WO2001060852A1 A 52 kDa PROTEIN FROM COAGULASE NEGATIVE STAPHYLOCOCCI AND FRAGMENTS THEREOF |
| 08/23/2001 | WO2001060849A2 Cold-adapted equine influenza viruses |
| 08/23/2001 | WO2001060847A2 Avirulent, immunogenic flavivirus chimeras |
| 08/23/2001 | WO2001060846A1 Cyclic hexapeptide derivatives |
| 08/23/2001 | WO2001060845A1 Novel echinocandin derivatives, preparation method and use thereof as fungicides |
| 08/23/2001 | WO2001060838A2 Aids ancestral viruses and vaccines |
| 08/23/2001 | WO2001060834A1 Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both |
| 08/23/2001 | WO2001060832A2 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 08/23/2001 | WO2001060829A1 Phosphororganic compounds and the use thereof |
| 08/23/2001 | WO2001060816A1 Kinase inhibitors |
| 08/23/2001 | WO2001060808A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | WO2001060801A2 9-alkylamino-1-nitroacridine derivatives |
| 08/23/2001 | WO2001060798A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | WO2001060409A1 Improved paste formulations |
| 08/23/2001 | WO2001060403A1 Gm-negative ehv-mutants |
| 08/23/2001 | WO2001060402A2 Proteosome influenza vaccine |
| 08/23/2001 | WO2001060382A1 Micelles |
| 08/23/2001 | WO2001060381A1 Nucleoside analogs with carboxamidine-modified bicyclic base |
| 08/23/2001 | WO2001060379A1 Nucleoside analogs with carboxamidine modified monocyclic base |
| 08/23/2001 | WO2001060378A2 Antiadhesive carbohydrates |
| 08/23/2001 | WO2001060374A1 Use of paullone derivatives for making medicines |
| 08/23/2001 | WO2001060369A1 Inhibitors of prenyl-protein transferase |
| 08/23/2001 | WO2001060367A1 Compositions comprising flavopiridol and their use for hiv therapy |
| 08/23/2001 | WO2001060366A1 Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 08/23/2001 | WO2001060349A2 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 08/23/2001 | WO2001060346A2 Nutritional formulation containing prebiotic substances |
| 08/23/2001 | WO2001060345A2 Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
| 08/23/2001 | WO2001060344A2 Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections |
| 08/23/2001 | WO2001060325A1 Pharmaceutical composition |
| 08/23/2001 | WO2001060315A2 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 08/23/2001 | WO2001060162A2 Cationic, amphipathic beta-sheet peptides and uses thereof |
| 08/23/2001 | WO2001012775A3 25 human secreted proteins |
| 08/23/2001 | WO2001012215A3 Protective antigen of Epstein barr virus |
| 08/23/2001 | WO2001010387A3 Antiviral therapy use of P-glycoprotein modulators |
| 08/23/2001 | WO2001008704A3 Dendrimer-photosensitizer complexes for medical applications |
| 08/23/2001 | WO2001007637A3 Conditionally controlled, attenuated HIV vaccine |
| 08/23/2001 | WO2000078266A3 Interferon tau mutants and methods for making them |
| 08/23/2001 | WO2000061737A3 Production of attenuated negative stranded RNA virus vaccines |
| 08/23/2001 | WO2000059484A3 Use of arylalkanoylpyridazines |
| 08/23/2001 | WO2000006738A3 NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 08/23/2001 | WO2000000615A3 Compounds and methods for the diagnosis and treatment of ehrlichia infection |
| 08/23/2001 | WO1999047639A3 Staphylococcus aureus genes and polypeptides |
| 08/23/2001 | US20010016660 Reacting difunctional alkanes containing halogen or aliphatic or aromataic sulfonyloxide reactive functional groups with 4-aminopyrimidine derivative in presence of water and organic solvent (alcohols, glycols, polyglycols, mono or diethers) |
| 08/23/2001 | US20010016583 Therapeutic application of pro-apoptotic benzodiazepines |
| 08/23/2001 | US20010016581 Separation of cephalosporin isomers |
| 08/23/2001 | US20010016574 9a,11b-dehydro derivatives of 9-oxime-3-keto-6-O- methylerythromycin |
| 08/23/2001 | US20010016568 Zinc chelate dimeric cell surface receptor antagonist |
| 08/23/2001 | US20010016346 Pedtidyl-prolyl cis-trans isomerase inhibitors and uses therefore |
| 08/23/2001 | US20010016336 Genetic engineered polypeptide |
| 08/23/2001 | US20010016199 Alphavirus RNA replicon systems |
| 08/23/2001 | US20010016197 Cultivating a fungi of the basidiomycetes in a submerged culture on nutrient media, isolating the biomass of edible mushrooms from the culture broth, and drying at a range of 40-45 degrees celsius |
| 08/23/2001 | EP1143944A3 Use of arylalkanoylpyridazines |
| 08/23/2001 | DE10006989A1 Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit |
| 08/23/2001 | CA2765218A1 Antiadhesive carbohydrates comprising a terminal uronic acid unit containing a carbon-carbon double bond |
| 08/23/2001 | CA2402440A1 Aids ancestral viruses and vaccines |
| 08/23/2001 | CA2400862A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 08/23/2001 | CA2400274A1 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 08/23/2001 | CA2400178A1 Nail lacquer pharmaceutical composition |
| 08/23/2001 | CA2399947A1 Phosphororganic compounds and the use thereof |
| 08/23/2001 | CA2399668A1 Cationic, amphipathic beta-sheet peptides and uses thereof |
| 08/23/2001 | CA2398872A1 Avirulent, immunogenic flavivirus chimeras |
| 08/23/2001 | CA2398861A1 Gene disruption methodologies for drug target discovery |
| 08/23/2001 | CA2397651A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | CA2397560A1 Use of paullone derivatives for making medicines |
| 08/23/2001 | CA2395854A1 Nucleoside analogs with carboxamidine-modified bicyclic base |
| 08/23/2001 | CA2337616A1 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/22/2001 | EP1125944A1 Pluraflavin and derivatives thereof, process for making them as well as their use |
| 08/22/2001 | EP1125938A1 Protein kinase inhibitors for treatment of neurological disorders |
| 08/22/2001 | EP1125936A2 Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases |
| 08/22/2001 | EP1125925A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1124983A1 Method for producing in vivo proteins chemically diversified by incorporating non-standard amino acids |
| 08/22/2001 | EP1124980A2 Method for the production of quercetin and isoquercetin derivatives |
| 08/22/2001 | EP1124968A2 Library of novel "unnatural" natural products |
| 08/22/2001 | EP1124966A1 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 08/22/2001 | EP1124965A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 08/22/2001 | EP1124852A1 Lysine-rich statherin protein |
| 08/22/2001 | EP1124850A1 12 human secreted proteins |
| 08/22/2001 | EP1124849A2 Chlamydia 98kd putative outer membrane protein and corresponding dna fragments and uses thereof |
| 08/22/2001 | EP1124848A2 Transmembrane 4 proteins |
| 08/22/2001 | EP1124839A2 Nucleosides with anti-hepatitis b virus activity |
| 08/22/2001 | EP1124837A2 Novel macrolide antibiotics |
| 08/22/2001 | EP1124831A2 Sodium salt of 3-(4-cinnamyl-1-piperazinyl)imino-methyl rifamycin sv and process of preparation |
| 08/22/2001 | EP1124815A1 Method for producing luteolin and luteolin derivatives |
| 08/22/2001 | EP1124813A1 Microbial transformation product |
| 08/22/2001 | EP1124811A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124810A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 08/22/2001 | EP1124809A1 Benzoylpyridazines |
| 08/22/2001 | EP1124779A1 Vitamin d analogues |
| 08/22/2001 | EP1124630A1 Method for preparing capsules consisting of a liquid active material core enclosed in a mineral coating |
| 08/22/2001 | EP1124592A2 Textured and porous silicone rubber |
| 08/22/2001 | EP1124577A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 08/22/2001 | EP1124576A2 Method for preparing solid phase conjugate vaccines |
| 08/22/2001 | EP1124575A1 Method for the production of an antiviral agent |
| 08/22/2001 | EP1124574A2 Component for vaccine against serogroup b meningococci |
| 08/22/2001 | EP1124573A1 Methods for treating sepsis |
| 08/22/2001 | EP1124565A1 Beta-l-2'-deoxy-nucleosides for the treatment of hiv infection |
| 08/22/2001 | EP1124562A1 Combination therapy to treat hepatitis b virus |
| 08/22/2001 | EP1124560A1 Use of antifungal agents for treating scleroses |
| 08/22/2001 | EP1124554A1 Pharmaceutical compositions containing tetrahydroisoquinoline compounds |
| 08/22/2001 | EP1124545A2 Use of estrogenic compounds as anti-fungal agents |